26.84
price down icon1.29%   -0.3537
 
loading
Alkermes Plc stock is traded at $26.84, with a volume of 93,763. It is down -1.29% in the last 24 hours and down -8.55% over the past month. Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$27.19
Open:
$27
24h Volume:
93,763
Relative Volume:
0.05
Market Cap:
$4.43B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
13.76
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-8.58%
1M Performance:
-8.55%
6M Performance:
-13.95%
1Y Performance:
+1.24%
1-Day Range:
Value
$26.75
$27.04
1-Week Range:
Value
$26.05
$29.59
52-Week Range:
Value
$25.56
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
Name
Alkermes Plc
Name
Phone
00-353-1-772-8000
Name
Address
CONNAUGHT HOUSE, DUBLIN 4
Name
Employee
1,800
Name
Twitter
@alkermes
Name
Next Earnings Date
2024-10-24
Name
Latest SEC Filings
Name
ALKS's Discussions on Twitter

Compare ALKS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
26.84 4.46B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
153.64 67.31B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.75 45.95B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.945 43.35B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.46 18.68B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
304.07 13.44B 2.99B 1.21B 1.13B 25.06

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-15-25 Initiated Goldman Buy
Jun-17-25 Upgrade UBS Neutral → Buy
May-28-25 Initiated Needham Buy
Mar-13-25 Initiated RBC Capital Mkts Sector Perform
Mar-04-25 Upgrade UBS Sell → Neutral
Feb-11-25 Initiated Deutsche Bank Buy
Nov-05-24 Upgrade Stifel Hold → Buy
Jun-17-24 Initiated TD Cowen Buy
Mar-19-24 Initiated Robert W. Baird Outperform
Feb-20-24 Downgrade UBS Neutral → Sell
Nov-20-23 Resumed JP Morgan Neutral
Oct-24-23 Upgrade Evercore ISI In-line → Outperform
Oct-17-23 Initiated UBS Neutral
Nov-03-22 Upgrade Piper Sandler Neutral → Overweight
Oct-14-22 Upgrade BofA Securities Underperform → Neutral
Aug-16-22 Initiated Piper Sandler Neutral
Apr-22-22 Resumed Goldman Buy
Apr-20-22 Initiated Goldman Buy
Jan-27-22 Upgrade Cantor Fitzgerald Hold → Overweight
Dec-01-21 Initiated Citigroup Neutral
Oct-07-21 Upgrade Jefferies Hold → Buy
Sep-02-21 Downgrade BofA Securities Neutral → Underperform
Oct-15-20 Upgrade Mizuho Neutral → Buy
Jul-30-20 Downgrade Goldman Neutral → Sell
Feb-14-20 Downgrade BofA/Merrill Buy → Neutral
Feb-14-20 Reiterated H.C. Wainwright Neutral
Feb-14-20 Downgrade JP Morgan Overweight → Neutral
Feb-06-20 Initiated Mizuho Neutral
Jan-31-20 Upgrade Wolfe Research Underperform → Peer Perform
Sep-05-19 Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-15-19 Upgrade Goldman Sell → Neutral
May-31-19 Initiated H.C. Wainwright Neutral
May-01-19 Downgrade Citigroup Buy → Neutral
Dec-19-18 Downgrade Goldman Neutral → Sell
Dec-14-18 Initiated Wolfe Research Underperform
Dec-13-18 Downgrade Credit Suisse Outperform → Underperform
Nov-05-18 Initiated Piper Jaffray Neutral
Aug-07-18 Initiated Stifel Hold
Jun-21-18 Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18 Initiated B. Riley FBR, Inc. Buy
May-16-18 Upgrade Citigroup Neutral → Buy
May-11-18 Initiated BofA/Merrill Buy
View All

Alkermes Plc Stock (ALKS) Latest News

pulisher
Jul 23, 2025

Abivax’s miRNA therapy emerges as a new mechanism for ulcerative colitis - biocentury.com

Jul 23, 2025
pulisher
Jul 23, 2025

Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Alkermes plc stockHigh-yield portfolio picks - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Alkermes plc Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Alkermes plc stock priceConsistently exceptional gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Alkermes plc a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - Yahoo Finance

Jul 22, 2025
pulisher
Jul 21, 2025

Alkermes Announces Positive Phase 2 Study Results - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com

Jul 21, 2025
pulisher
Jul 21, 2025

Jefferies Raises Target for Alkermes (ALKS) Following Promising Drug Data | ALKS Stock News - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. - inkl

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive

Jul 21, 2025
pulisher
Jul 21, 2025

Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Jul 21, 2025
pulisher
Jul 20, 2025

Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛

Jul 20, 2025
pulisher
Jul 19, 2025

10 Most Undervalued Pharma Stocks To Buy Now - Insider Monkey

Jul 19, 2025
pulisher
Jul 17, 2025

BlackRock increases stake in Alkermes to 17.05% By Investing.com - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

BlackRock increases stake in Alkermes to 17.05% - Investing.com

Jul 17, 2025
pulisher
Jul 15, 2025

Alkermes to Release Q2 Financial Results on July 29, 2025 - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Alkermes to Report Second Quarter Financial Results on July 29, 2025 - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Expert Outlook: Alkermes Through The Eyes Of 6 Analysts - Benzinga

Jul 15, 2025
pulisher
Jul 15, 2025

Goldman Sachs Initiates Coverage on Alkermes (ALKS) with a Buy R - GuruFocus

Jul 15, 2025
pulisher
Jul 14, 2025

How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 08, 2025

Alkermes (NASDAQ:ALKS) shareholders have earned a 9.3% CAGR over the last five years - simplywall.st

Jul 08, 2025
pulisher
Jul 03, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance

Jul 03, 2025
pulisher
Jun 30, 2025

Alkermes plc(NasdaqGS: ALKS) added to Russell 2500 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 26, 2025

Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial - MSN

Jun 26, 2025
pulisher
Jun 23, 2025

(ALKS) On The My Stocks Page - news.stocktradersdaily.com

Jun 23, 2025

Alkermes Plc Stock (ALKS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Alkermes Plc Stock (ALKS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Nichols Christian Todd
SVP, Chief Commercial Officer
Jun 10 '25
Sale
31.09
3,334
103,654
86,208
$72.67
price down icon 0.97%
$14.99
price up icon 0.13%
$9.38
price up icon 0.05%
drug_manufacturers_specialty_generic RDY
$14.71
price up icon 0.68%
$133.59
price down icon 0.17%
$303.41
price down icon 0.17%
Cap:     |  Volume (24h):